NASHVILLE, Tenn., June 19 /PRNewswire/ -- Nashai Biotech, LLC, a product research, development and procurement company for nutritional supplements, over-the-counter medications and active pharmaceutical ingredients (APIs), today announced that its patent-pending process successfully preserves and protects theaflavins as active ingredients from raw material to finished product. Nashai processes meet bulk API and current good manufacturing practices (cGMP).
"Over the past few years, Nashai has developed processes for extracting theaflavins from tea," says Michael Vaughn, president and CEO of Nashai Biotech. "Researchers have found that theaflavins degrade and lose their active properties when they are made into a powder or liquid and are exposed to the natural environment. Nashai's proprietary technology preserves and protects the active ingredient theaflavin, ensuring bioavailability, as well as safety and shelf life for two years."
Theaflavins are unique active ingredients, which are produced when green tea ferments and changes into black or oolong tea. Nashai Biotech developed standard operating procedures for extracting and testing theaflavins that have been validated and duplicated by independent laboratories in the United States and further tested for contaminants.
"Nashai's proprietary nutritional supplement, called Teaflavin(R), was developed and tested as though it were an active pharmaceutical ingredient," adds Jim Zhao, Ph.D., Chief Science Officer of Nashai Biotech, pointing out that tea scientists recognize the medicinal benefits of theaflavins and have studied their positive effects on cardiovascular health, cancer, immune system, metabolism, diabetes and other areas.
Teaflavin(R) has undergone extensive testing, in both animals and humans, including two years of actual stability, safety and toxicity tests as well as testing for pesticides, herbicides and heavy metals. Proven to be safe and efficacious, Teaflavin(R) originates as organically grown tea, and the finished product is GMO-free and PCR negative.
"We know that as the research and interest in theaflavins continue to grow, pirate raw material suppliers and marketers will try to copy our products and sell tea extracts that claim to have various levels of theaflavins to compete with Nashai Biotech's product Teaflavin(R)," continues Vaughn. "Our integrated extraction process is seamless, and we know that theaflavins are unstable and degrade when encapsulated in a two-piece hard shell or in a tablet. We intend to vigorously protect and defend our intellectual property so as to maintain the integrity of our product."
Teaflavin(R) will be marketed by Nashai through exclusive licensing agreements in multiple distribution channels. Nashai Biotech has located its U.S. offices in the Cumberland Emerging Technologies Center, in downtown Nashville, Tenn. Nashai Biotech has been accepted for membership in the Council for Responsible Nutrition, one of the dietary supplement industry's leading trade associations.
"In cooperation with leading international cardiologists at academic medical centers, the Tennessee biotech community and industry partners, Nashai Biotech is positioned to capitalize on its broad base of clinical research and intellectual property to demonstrate the effectiveness of science-based nutritional supplements as cost-effective, meaningful solutions for preventive healthcare," says Vaughn.
About Nashai Biotech, LLC
Headquartered in Nashville, Tennessee with offices in Irvine, California and Shanghai, China, Nashai Biotech, LLC (www.nashai.com) produces patented, new generation formulas and ingredients based upon compelling scientific evidence. Nashai researches, develops and produces novel ingredients, converted into dietary supplements, over-the-counter medicines and active pharmaceutical ingredients, for distribution to the consumer by pharmaceutical and natural products companies with well-established marketing and distribution networks.